{
  "symbol": "BIIB",
  "price": 154.22,
  "beta": 0.112,
  "volAvg": 1482682,
  "mktCap": 22610903304,
  "lastDiv": 0,
  "range": "110.04-194.13",
  "changes": 14.14,
  "companyName": "Biogen Inc.",
  "currency": "USD",
  "cik": "0000875045",
  "isin": "US09062X1037",
  "cusip": "09062X103",
  "exchange": "NASDAQ Global Select",
  "exchangeShortName": "NASDAQ",
  "industry": "Drug Manufacturers - General",
  "website": "https://www.biogen.com",
  "description": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.",
  "ceo": "Christopher A. Viehbacher",
  "sector": "Healthcare",
  "country": "US",
  "fullTimeEmployees": "7605",
  "phone": "617 679 2000",
  "address": "225 Binney Street",
  "city": "Cambridge",
  "state": "MA",
  "zip": "02142",
  "dcfDiff": -214.6784,
  "dcf": 368.8983983679785,
  "image": "https://images.financialmodelingprep.com/symbol/BIIB.png",
  "ipoDate": "1991-09-17",
  "defaultImage": false,
  "isEtf": false,
  "isActivelyTrading": true,
  "isAdr": false,
  "isFund": false
}